Top of FormMed-tech financings in March totaled $1.79 billion. Although a decline from February’s total, the cumulative value for the first three months of the year reached $6.02 billion, an increase from $4.69 billion during the same period the previous year.

In February 2024, BioWorld covered 236 updates on phase I-III clinical trials, showing a 6.35% decline from January 2024’s 252 updates. This figure is also lower than February 2023’s count of 258 updates. Throughout 2023, the monthly average of phase I-III updates was 305, with 2024 having an average of 244 in the first two months of the year.